ChemoCentryx (CCXI), Vaxart (VXRT) stocks rally on upbeat drug news

Follow us on Google News:
 ChemoCentryx (CCXI), Vaxart (VXRT) stocks rally on upbeat drug news
Image source: Khakimullin Aleksandr,Shutterstock


  • FDA has approved ChemoCentryx's drug Avacopan, to be sold under the brand name Tavneos.

  • A Duke University study showed Vaxart's oral drug is more effective in reducing SARS-CoV-2 transmission.
  • Vaxart, Inc. (NASDAQ: VXRT) stock surged 12% YTD, while ChemoCentryx Inc. (NASDAQ: CCXI) stock fell 66.72% YTD.

Stocks of ChemoCentryx, Inc. (NASDAQ: CCXI) and Vaxart, Inc. (NASDAQ: VXRT) caught investors' eyes on Friday after sharing upbeat news on the drug front.

The CCXI stock jumped 92%, while the latter rose 7% in the premarket session.

CCXI traded at US$37.74, up 92.55%, while VXRT traded at US$7.61, up 7.33%, at around 8 am ET from their previous closing prices.

Here are some recent developments of the two companies.

Also Read: Is Affirm (AFRM) on course to become the next PayPal?

ChemoCentryx, Inc. (NASDAQ: CCXI)

ChemoCentryx is a biopharmaceutical company based in San Carlos, California. It develops oral drugs for treating autoimmune diseases, cancer, and other diseases.

On Friday, the company said that the US Food and Drug Administration (FDA) approved its leading oral drug Tavneos (Avacopan), for treating the autoimmune disease.

The Avacopan formulation is sold under the brand Tavneos. It is expected to be available in the clinics in the next few weeks, the company added.

Also Read: Will these Chinese stocks benefit from a Biden-Xi summit?

ChemoCentryx has a market cap of US$1.37 billion and a forward P/E one year of -10.59. Its EPS is US$-1.77. Its stock value fell 66.72% YTD.

The 52-week highest and lowest stock prices were US$70.29 and US$9.53, respectively. Its trading volume was 6,174,183 on October 7.

The total revenue of the company was US$1.81 million in Q2, FY21, compared to US$49.44 million in the year-ago quarter. It reported a net loss of US$39.20 million against an income of US$20.26 million in Q2, FY20.

Also Read: Paltalk (PALT) & Matterport (MTTR): Two trending stocks on Thursday

ChemoCentryx (CCXI) and Vaxart (VXRT) stocks rally on drug news.

Also Read: Why did Oatly (OTLY), Arrival (ARVL) stocks pop in intraday trading?

Vaxart, Inc. (NASDAQ: VXRT)

Vaxart is a biotechnology company based in San Francisco, California. It develops oral recombinant vaccines using temperature-stable tablets, according to the company.

The VXRT stock surged after a Duke University study of Vaxart's oral tablet showed positive results in reducing SARS-CoV-2 transmission in animals. The drug is currently under review. The study showed the pill was more effective than the injectable flu vaccines.

Also Read: US stocks rally on Senate debt-ceiling extension deal

Vaxart’s market cap is US$888.17 million, and the forward P/E one year is -10.43. Its EPS is US$-0.48. The stock value of VXRT jumped 12.01 percent YTD. The 52-week highest and lowest stock prices were US$24.90 and US$3.50, respectively. Its share volume on October 7 was 5,641,791.

Its total revenue was US$0.11 million in Q2, FY21, compared to US$0.52 million in the same quarter of the previous year. It reported a net loss of US$16.11 million, or US$0.13 per share, against a loss of US$8.97 million, or US$0.12 per share, in Q2, FY20.

Also Read: Are these stocks safe from inflation, currency fluctuations?


The healthcare sector saw rapid growth during the pandemic, boosted by drug developments, research, and rapid approvals, especially for Covid-19 vaccines. The S&P 500 healthcare sector grew by 12.32 percent YTD, suggesting its sustained growth. However, investors should evaluate the companies carefully before investing in the stock market.


The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.

Featured Articles